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Abstract
Objective 
Intractable epilepsy is a serious neurologic problem with different etiologies. 
Decreased levels of pyridoxal phosphate in cerebral spinal fluid of patients 
with intractable epilepsy due to pyridoxine dependency epilepsy are reported. 
The aim of this study was to compare plasma pyridoxal 5´-phosphate level in 
patients with intractable and controlled epilepsy.
Materials & Methods
This cross- sectional analytic study included 66 epileptic children, 33 patients 
with controlled and 33 patients with intractable epilepsy, after neonatal period 
up to 15 yr old of age. Thirty-three patients with intractable epilepsy (10-
162 months) and 33 patients with controlled epilepsy (14-173 months) were 
enrolled. The study was conducted in Pediatric Neurology Clinic of Mofid 
Children Hospital, Tehran, Iran from January 2010 to December 2010. 
Patients’ clinical manifestations, laboratory and neuroimaging findings were 
collected. Non-fasting plasma 5´- pyridoxal phosphate levels of these subjects 
were assessed by high-pressure liquid chromatography.
Results
Mean plasma 5´- pyridoxal phosphate level (PLP) in patients with controlled 
epilepsy was 76.78±37.24 (nmol/l) (15.5-232.4). In patients with intractable 
epilepsy, mean plasma 5´- pyridoxal phosphate was 98.67± 80.58 (25.5-
393) nmol/l. There was no statistically significant difference between plasma 
pyridoxal phosphate levels of these two groups (P═0.430).
Conclusion
Pyridoxine dependent epilepsy is under diagnosed because it is manifested 
by various types of seizures. Plasma pyridoxal phosphate levels did not differ 
in our patients with intractable or controlled epilepsy. If PDE is suspected 
on clinical basis, molecular investigation of ALDH7A1 mutations, as feasible 
test, until PDE biomarkers becomes available is recommended.
Keywords: Pyridoxine Dependent Epilepsy; Intractable Epilepsy; Plasma 
Pyridoxal Phosphate Level; Children
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Introduction 
Seizure is a common neurologic problem. The incidence of epilepsy in children up 
to 15 yr old is reported 5-7 cases per 10000 (1). 
Antiepileptic drugs (AEDs) as first modality of seizure treatment usually produce 
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patients.
Material & Methods 
This case control study was conducted in Pediatric 
Neurology Clinic of Mofid Children Hospital, Tehran, 
Iran from January 2010 to December 2010, a referral 
and teaching hospital. 
Patients with epilepsy after neonatal period up to 15 
years old were included in the study. Exclusion criteria 
were 1- therapeutic vitamin B6 therapy during past 
six months, 2- intractable epilepsy due to a known 
symptomatic cause (neurocutaneous disease, brain 
structural anomalies or dysgenesis, brain tumor …). 
This study was confirmed by the Ethics Committee 
of Shahid Beheshti University of Medical Sciences. 
Informed consent form was completed by parents.
Patients based on their seizures´ responses to antiepileptic 
drugs were classified as intractable or controlled epileptic 
cases. Children with seizures without therapeutic 
response to at least two appropriate antiepileptic drugs 
with optimum dose for more than two weeks were 
considered as intractable epileptic patients. Controlled 
epileptic patient was defined as a child whose seizures 
were controlled by maximum two antiepileptic drugs for 
at least six months. Thirty-three patients with refractory 
epilepsy were matched with 33 patients with controlled 
epilepsy as control group for age, sex, seizure type and 
family history of seizure. 
Demographic, historical, physical examination, 
neuroimaging, electroencephalograms and laboratory 
data were recorded in a questionnaire by a child 
neurologist. Five millilitres blood was taken from each 
not fasting subject in vacutainers containing EDTA 
between 8 and 10 a.m. The samples were kept in crushed 
ice and protected from light. After centrifuge, plasma 
was frozen at -10 ˚C for future plasma PLP analyses.
Plasma PLP levels were measured using high-pressure 
liquid chromatography (HPLC) method with Young-
lin Instrument (South Korea). Intra-day coefficient of 
variation (CV) was less than 6% and inter-day (day-
to-day) CV was less than 10%. Plasma pyridoxal 
5’-phosphate deficiency was defined as PLP level less 
than 20 nmol/l (13).
Categorical variables were analysed using Chi-square 
test. Continuous variables were analysed using t test or 
good seizure control in patients. At least 20% of children 
with seizure disorders on appropriate AEDs have 
recurrent seizures, intractable or uncontrolled epilepsies 
(2). 
Pyridoxine dependency epilepsy (PDE) is one of the 
important and treatable causes of intractable epilepsies 
(3). In addition to PDE, some seizures in children may be 
controlled by administering pyridoxine as a antiepileptic 
drug (PRS) (4). In a study in IR.Iran, three of thirty 
infants and children with intractable epilepsy became 
seizure free with oral high dose of pyridoxine as adjunct 
to other AEDs (5). In a hospital based study in India, 
7.4% of patients with intractable early onset cryptogenic 
epilepsy were diagnosed as definite cases of PDE (6).
Baxter classified PDE based on clinical criteria, control 
or recurrence of seizure after an experimental trial of 
pyridoxine administration and withdrawal to definite, 
probable and possible PDE (7). Due to different classic 
and atypical presentation of PDE and lack of specific, 
available biomarkers, only a few case reports are 
available, probably because of under diagnosing (8).
Pyridoxal 5´-phosphate (PLP) is the major component 
of different pyridoxine vitamers in plasma (9). PLP is 
the main vitamer of B6 vitamin, which contributes as a 
cofactor in more than 100 enzyme-catalyzing reactions 
including different amino acids and amines in central 
nervous system (neurotransmitters) metabolic pathways 
(10). Low level of PLP in the brain results in neurological 
dysfunction, such as seizurs (11). Decreased level of 
PLP in cerebrospinal fluid (CSF) was seen in some cases 
of intractable epilepsy, PDE, pyridoxine phosphate 
oxidase deficiency and molybdenum cofactor deficiency 
(12). Low concentration PLP level in the brain can be 
presented with symptomatic neurological disorders. Low 
level of PLP in cerebrospinal fluid has been reported 
in intractable epilepsy previously (11, 12). Plasma 
PLP level is a measure to determine the adequacy of 
pyridoxine intake in human (13, 14). Decreased PLP 
level in CSF with normal plasma PLP level was reported 
in neonates with PDE (15). Despite this finding, study of 
Spanish patients with PDE showed some patients with 
PDE had low level of plasma PLP before pyridoxine 
treatment (16).
This study aimed to determine the value of plasma PLP 
level measurement in intractable and controlled epileptic 
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(14). In this study, 2 patients with controlled epilepsy 
and 2 patients with intractable epilepsy had plasma 
PLP level less than 30 nmole/l. Pyridoxine treatments 
did not decrease number and frequency of seizures in 
these intractable epileptic patients, although they had 
been treated with high dose pyridoxine. These findings 
warrants study about adequacy of vitamin B6 intake in 
our children and importance of daily multivitamin intake 
in epileptic patients on AED therapy.
Classical PDE was described as prolonged, recurrent 
or intractable seizures in neonates and infants, without 
response to different AEDs but eventually intravenous 
pyridoxine administration control these seizures. 
PDE may present with atypical manifestation. Such 
presentations include: seizure onset after neonatal 
and infancy period (up to three years old), seizures 
that control by AEDs at first and later recurrence as 
intractable seizures, seizures that do not respond to 
pyridoxine immediately but finally will control later by 
it and longer interval between pyridoxine withdrawal 
and seizure recurrence (7,17).  
Due to different seizure types and variable PDE 
manifestation, classical and atypical presentation, 
lack of pathognomonic electroencephalography or 
neuroimaging findings, an available, specific and non-
invasive test will help to confirm it, in shorter time.
Early diagnosis and treatment help to prevent or 
decreased adverse neurological outcomes of prolonged 
or intractable seizures.
Such tests will eliminate need to experimental Baxter trial 
(pyridoxine stopping and waiting to seizure recurrence 
in patients whose intractable seizures were responded to 
pyridoxine) to prove PDE. 
There are a few case reports during sixty years after 
PDE introduction in medical literature. Exact incidence 
of PDE in world is unknown. PDE incidence is reported 
from 1:20000 in a neonatal center study in Germany to 
about 1:700000 in United Kingdom (7, 18). This wide 
range partly is related to difference of two these study 
design. Studies have shown low PLP level in CSF of 
patients with PDE (12). PLP contributes as a cofactor in 
many neurotransmitters metabolisms in central venous 
system including gamma amino butyric acid (GABA) 
(10). Some studies tried to determine cut off value for 
PLP contents of CSF in different pediatric age groups (19-
Mann Witney U test where appropriate.
 
Results 
Thirty-three patients with intractable epilepsy (10-
162 months) and 33 patients with controlled epilepsy 
(14-173 months) were enrolled (Table 1). There was 
no statistically significant difference between two 
groups in terms of weight, parents consanguinity, 
daily multivitamin intake, seizure type (partial versus 
generalized). The differences for seizure age of onset, 
EEG, motor delay, cognition delay and speech delay 
between two groups were statistically significant.
Mean plasma pyridoxal phosphate level (PLP) in patients 
with controlled epilepsy was 76.78±37.24 (nmol/l) 
(15.5-232.4). In patients with intractable epilepsy, mean 
plasma pyridoxal level was 98.67± 80.58 (25.5-393) 
nmol/l. There was no statistically significant difference 
between plasma pyridoxal phosphate levels of these two 
groups (P= 0.430). 
Only one 38 months old male patient with controlled 
epilepsy on primidon therapy had plasma pyridoxal 
phosphate deficiency (PLP level: 15.5 nmol/l). His 
seizure onset was before 3 yr old. His neuroimaging, 
EEG, developmental indices were normal. He did not 
use daily multivitamin.
Discussion 
In this study, we did not find any significant statistical 
difference in plasma level of 5´- pyridoxal phosphate 
in patients with intractable or controlled epilepsy. Only 
one of our patients with controlled epilepsy on primidon 
therapy, without multivitamin intake, had plasma PLP 
level < 20 nmol/l. In a large population study, 25% of 
children < 13 yr old who did not use B6 supplement 
and 11% of same age group on vitamin B6 intake, 
had plasma PLP <20 nmol/l (14). Four of our patients 
had plasma PLP level < 30 nmol/l. They consisted of 
one male and one female patients with intractable and 
two male patients with controlled epilepsy. These 
patients did not use multivitamin daily, despite most 
of our patients who were on daily multivitamin intake, 
especially whom were on old AED therapy. Plasma PLP 
< 30 nmol/L has been reported in 25% of third grade 
elementary school children (8-9 yr old) in Indonesia. 
These children did not get any drug or multivitamin 
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who are suspected to have PDE on clinical basis in whom 
biomarker testing in not achievable or in patients with 
elevated urinary α-AASA or P6c and PA to establish 
PDE diagnosis, too (25). 
In conclusion, Pyridoxine dependent epilepsy is under 
diagnosed because it is manifested by various types 
of seizures. Plasma pyridoxal phosphate levels did 
not differ in our patients with intractable or controlled 
epilepsy. If PDE is suspected on clinical basis, 
molecular investigation of ALDH7A1 mutations, as 
feasible test, until PDE biomarkers becomes available 
is recommended. 
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20). Measurement of PLP level in CSF of patients with 
intractable epilepsy is a diagnostic test, but it is invasive 
and nonspecific. Decreased PLP concentration in CSF 
is seen in pyridoxine phosphate oxidase deficiency and 
molybdenum cofactor deficiency in addition to PDE.
In patients with PDE, cerebral PLP activity reduces 
through cerebral lysine catabolism. Increase in alpha 
aminoadipic semi aldehyde (α-AASA) concentration 
occurs due to alpha aminoadipic semi aldehyde 
(α-AASA) dehydrogenase or antiquitin (ATQ) enzyme 
deficiency. Delta 1piperideine-6-carboxylate (P6C) 
is cyclic form α-AASA. These two components 
are in a spontaneous equilibrium in central nervous 
system. Increased cerebral P6C concentration through 
knoevengal condensation, reduce cerebral PLP 
activity (21). Elevated level of pipecolic acid (PA), an 
intermediate product of lysine catabolism, in plasma and 
/ or CSF was the first biomarker for PDE diagnosis (18).
Increased PA concentration are seen in different 
conditions including liver diseases, peroxisomal disorders 
such Zellweger syndrome (22). Low CSF / plasma ratio 
of PA in these situations help to differentiate them from 
PDE (21). Increased urinary α-AASA excretion due to 
its accumulation in various body fluids (plasma, CSF, 
urine) has been introduced as a noninvasive, powerful 
and simple biomarker for PDE diagnosis, recently (23). 
Increased α-AASA urinary excretion is reported in other 
neurologic disorders including molybdenum cofactor 
and sulfite oxidase deficiencies (24). Increased urinary 
P6C excretion has been introduced as new biomarker, 
comparable with elevated urinary α-AASA excretion, 
in patients with PDE (25). Availability of these new 
biomarkers in some parts of the world is limited, 
because careful handling and proper freezing of urinary 
samples are essential to reliable interpretation of these 
tests (26, 27). Recently, Jung et al. suggested neonatal 
dried bloods spots for PDE screening (28). However, a 
sensitive biomarker as a screening tool for PDE is not 
available, yet.
Using molecular basis test, mutations of ALDH7A1 or 
antiquitin (ATQ) gene, in majority of patients with PDE 
have been reported. This gene is located on chromosome 
5q31and encode α-AASA protein. ALDH7A1 mutations 
study was introduced for prenatal diagnosis of PDE at 
first (23). Today it is used to confirm PDE in patients 
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